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Health economics of renal replacement therapy: Perspectives
from Singapore. The prevalence of end-stage renal disease
(ESRD) in Singapore is high and projected to increase sharply
due to the aging population and the high prevalence of diabetes.
The number of patients treated with dialysis was projected to
rise from 2633 in 1999 to nearly 6000 in the year 2010. The cost
of dialysis provision was estimated to increase 2.5-fold from
S$90 million in 1999 to S$241 million in 2010. To address this, the
Singapore Ministry of Health launched three initiatives in the
year 2000: First, to reduce the incidence of ESRD through (1)
primary prevention of diabetes, (2) community-based screen-
ing to facilitate early detection of patients with diabetes, (3)
improving glycemic and blood pressure (BP) control of dia-
betics in the primary care setting, and (4) the establishment
of dedicated Renal Retardation clinics to optimize BP control
(and glycemic control for diabetics), and reduce the level of
proteinuria in patients at high risk of ESRD development. Sec-
ond, to increase the percentage of ESRD patients treated with
continuous ambulatory peritoneal dialysis (CAPD), which is
a lower-cost modality compared with hemodialysis; and third,
amendments to the existing opt-out legislation for organ pro-
curement for transplantation to increase the supply of kidneys
for cadaveric renal transplant.
The prevalence of end-stage renal disease (ESRD) in
Singapore is high and is projected to continue to rise
rapidly, fueled by the aging of the population and the
high prevalence of diabetes mellitus. Developing effec-
tive public health strategies to contain the rising incidence
of ESRD, and evolving a sustainable model of renal re-
placement therapy provision and financing in order to
manage escalating costs are major challenges for the
health care system in Singapore.
Burden of ESRD in Singapore
The incidence of ESRD patients treated with dialysis
in Singapore increased from 142 per million population
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(pmp) in 1998 to 157 pmp in 2000 [1]. The prevalence
of ESRD patients on dialysis increased 7% during the
same period from 789 pmp in 1998 to 848 pmp in 2000
[1]. Diabetic nephropathy was the most common cause
of ESRD in new patients starting dialysis, accounting for
47.2% of cases in Singapore [1].
Serial community-based National Health Surveys car-
ried out by the Singapore Ministry of Health showed that
the prevalence of diabetes in the adult population has in-
creased from 2.5% in 1975 to 4.7% in 1984 to 8.6% in 1992
and 9.0% in 1998 [2]. Alarmingly, among those aged 60 to
69 years, the prevalence of diabetes was 32% in 1998. Of
concern, the 1998 National Health Survey also showed
that only 27.5% of adult diabetic patients had a HbA1c
level of 7.0% or less, while the mean HbA1c overall was
8.5%. For patients with hypertension, only 29.6% had
blood pressure readings of ≤140/80 mm Hg [3].
Dialysis provision and funding in Singapore
The provision and funding of dialysis treatment in
Singapore has a number of unique features. First, as with
other forms of medical treatment, Singaporeans rely on
Medisave (a compulsory savings scheme which together
with a matching contribution from employers, can be
used to pay for hospitalization and other expenses) and
Medishield (a basic, low-cost national castastrophic ill-
ness insurance scheme) to pay for a substantial propor-
tion of the treatment cost for dialysis. Second, voluntary
welfare organizations (VWO) such as the Singapore Na-
tional Kidney Foundation are dominant providers of dial-
ysis, raising sufficient funds from the public to provide
high-quality, low-cost dialysis treatments for a large num-
ber of ESRD patients. In the year 2000, the NKF provided
for 66% of hemodialysis patients in Singapore. Third, the
principle of personal responsibility for health and medical
care is a central tenet of Singapore’s health care financing
framework, and patient copayment is a key feature of the
system, which also applies to dialysis treatment.
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Table 1. Percentage of patients on peritoneal dialysis and
hemodialysis in Singapore from 1996 to 2003
On peritoneal dialysis On hemodialysis
Year Total N (%) N (%)
1996 1855 425 (22.9%) 1430 (77.1%)
1998 2392 404 (16.9%) 1988 (83.1%)
2000 2954 504 (17.1%) 2450 (82.9%)
2001 3094 547 (17.7%) 2547 (82.3%)
2002 3157 730 (23.1%) 2427 (76.9%)
2003 3462 794 (22.9%) 2668 (77.1%)
Three key challenges
In a major review of dialysis provision and funding
in Singapore in the year 2000, the Ministry of Health
noted three key challenges. First, the burden of ESRD
and the cost of providing dialysis treatment were likely
to increase sharply. Estimates based on Singapore’s aging
demographics, age-specific ESRD incidence rates, ESRD
patient mortality rates and renal transplants, and the ris-
ing prevalence of diabetes mellitus, suggested that the
number of patients requiring dialysis in Singapore will
have doubled from 2633 in 1999 to nearly 6000 in the
year 2010. This means an average net increase of about
300 patients requiring dialysis each year. These projec-
tions, which were carried out in the year 2000, do not
appear to be too far off because at end 2003, there was a
total of 3462 patients on dialysis.
In the year 2000, the Ministry of Health estimated that
the direct cost of dialysis provision and its associated ser-
vices was in excess of S$90 million or about S$36,000 per
patient per year. Based on the projected increase in pa-
tients requiring dialysis, it was estimated that in 2010, the
cost of dialysis provision would have increased 2.5-fold
to S$241 million per year.
Second, the majority of ESRD patients were on
hemodialysis, even though the overall cost of peritoneal
dialysis was lower [4]. The temporal trend in the percent-
ages of patients on hemodialysis and peritoneal dialysis
from 1996 to 2000 is shown in Table 1, together with data
from 2001 to 2003 after changes to the government sub-
sidy system for dialysis were made.
The overall cost of continuous ambulatory peritoneal
dialysis (CAPD) treatment was approximately S$1300
per month, compared with S$1800 to S$2400 per month
for hemodialysis in a stand-alone, VWO-run center, and
S$2700 per month for hemodialysis in a hospital-based
center.
The main reasons for these trends were the ready avail-
ability of high-quality hemodialysis provided by VWOs at
affordable charges to the patient, and the relatively lim-
ited government subsidies for CAPD at that time, which
meant that the out-of-pocket payments were often more
if patients chose CAPD.
Third, as the rate of growth of new dialysis patients
in the VWO centers grew at a faster pace than in the
hospital-based centers, the proportion of elderly patients
with multiple medical comorbidities in the former be-
came higher. For example, the percentage of patients over
the age of 65 years old dialyzing in NKF centers increased
from 16% in 1999 to 22% in 2002 [5]. From a health care
provision point of view, this was suboptimal because such
patients often require more intensive supervision during
dialysis, which would be better provided by a hospital-
based center and, hence, also justifying the higher cost
structure for such centers. In contrast, the VWO cen-
ters are situated within residential areas and are not well
suited for dialyzing patients who are less stable or who
have severe concomitant medical conditions.
Strategies to ameliorate the burden of ESRD
To address these challenges, the Ministry of Health
launched three major initiatives in the year 2000.
Greater emphasis and funding placed on prevention
of ESRD
Three major programs were: (1) The primary preven-
tion of diabetes through control and prevention of obe-
sity, and early diagnosis of diabetes through a national
community-based screening program. These efforts have
been described elsewhere [6]. The key target is to keep
the proportion of Singaporeans aged 18 to 69 years who
have diabetes to not more than 10%. At the same time,
because the 1998 National Health Survey found that 62%
of persons with diabetes were not aware that they had
the condition, a second target was to decrease, through
screening, the proportion of persons with diabetes whose
condition has been undiagnosed to <40% in 2010. (2)
Improving the level of glycemic control in diabetic pa-
tients treated in the primary care setting. Approximately
one third of diabetic patients in Singapore are cared for
in government-subsidized polyclinics. A target was set to
increase the proportion of diabetics who have optimal
blood glucose control (HbA1c ≤7.0%) in polyclinics to
>50% by 2010. Polyclinics took major steps to standard-
ize the process of care for diabetics, employed more nurse
counselors, and actively tracked the average HbA1c lev-
els achieved at six monthly intervals. For the period May
2002 to April 2003, an external audit by the Ministry of
Health showed that the average HbA1c of diabetic pa-
tients treated in the 17 polyclinics was 7.7%, and about
37% of patients had HbA1c ≤7.0%. (3) A program aimed
at retarding renal disease progression in patients at high
risk of developing ESRD. In the year 2001, the Ministry
of Health provided S$6.1 million to set up dedicated Re-
nal Retardation Clinics in two tertiary hospitals. Patients
were enrolled into these clinics if they had one or more
of the following: diabetes with proteinuria >1 g/day, pro-
teinuria >1 g/day from hypertension or any renal disease,
any cause of renal failure with serum creatinine >141 but
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Table 2. Data on proteinuria (g/day) and BP (mm Hg), and on HbA1c (%) for patients who also had diabetes after 12 months of treatment in the
Renal Retardation Clinics
Diabetic patients
Months Mean proteinuria g/day Number of patients BP mm Hg Number of patients Mean HbA1c % Number of patients
Baseline 2.9 817 143/81 817 8.0 520
3 3.3 411 142/79 647 7.7 321
12 2.6 151 139/78 282 7.8 176
% with proteinuria
reduced to <1 g/day
or a 50% reduction
from baseline =
47.9%
% of patients with
BP ≤140/90 mm
Hg = 62.4%




<500 lmol/L. The aims of treatment in these patients
included maintaining an HbA1c <7% for diabetics with
normal serum creatinine, maintaining BP <140/90 mm
Hg, and reducing proteinuria by 50% or to <1 g/day at the
end of one year through the use of angiotensin-converting
enzyme (ACE) inhibitors and/or angiotensin II receptor
blockers.
To date, 817 patients have been entered into this
program, 597 of whom are diabetics. The mean serum
creatinine at enrolment was 176 lmol/L, and mean pro-
teinuria was 2.96 g/day. For those with diabetes, mean
HbA1c at enrolment was 8.0%. While it is far too early
to determine the effectiveness of this approach, a pre-
liminary review of the data showed that at the end of
12 months, 47.5% of the patients with diabetes had an av-
erage HbA1c ≤7%, 62.4% of patients with hypertension
achieved a BP ≤140/90 mm Hg, and 47.9% had protein-
uria reduced to less than 1 g/day or a 50% reduction from
baseline. These data are summarized in Table 2. At the
end of 12 months of follow-up, 13 of 136 patients (9.6%)
showed a doubling of their serum creatinine level com-
pared with baseline.
Promoting CAPD as the dialysis modality of choice for
ESRD patients
A target was set to increase the proportion of patients
on CAPD to 35% by 2005 and 40% by 2010. To achieve
this, the levels of government subsidy for CAPD were in-
creased vis-a-vis hemodialysis, so that out-of-pocket pay-
ments for patients, after taking into account the amounts
that could be covered by the patients’ Medisave and
Medishield, would be less for CAPD than for hemodialy-
sis at a VWO center. A provision was made for higher
government subsidy for VWO-hemodialysis for those
ESRD patients for whom CAPD was not the preferred
modality for medical reasons. Public hospitals providing
hospital-based hemodialysis were restricted to accepting
only high-dependency cases (i.e., patients who were el-
derly and/or have concomitant medical problems that
could make them more unstable during dialysis). In par-
allel with this, increased educational efforts were made
to improve the publics’ and patients’ awareness and un-
derstanding of CAPD. The initiative enjoyed the strong
support of nephrologists who played an important role in
helping to drive the change.
The results of this initiative are summarized in Table 1.
The percentage of patients on CAPD increased from
about 17% in the period 1998 to 2000, to 23% in 2003.
In 2003, of 420 new ESRD patients who were started on
dialysis programs in the public hospitals, 42% opted for
CAPD.
Increasing the potential supply of cadaveric kidneys for
renal transplantation
Since 1987, Singapore has had an “opt-out” legislation,
the Human Organ Transplant Act, which allows for re-
moval of the kidneys from eligible Singaporeans who are
brain dead from accidental causes for the purposes of
renal transplantation. In 2004, the Human Organ Trans-
plant Act was amended. One of the key changes was the
extension of the act to cover the retrieval of organs from
eligible persons who are brain dead from all causes, and
not just accidents. It is estimated that this could increase
the number of cadaveric kidneys available for transplan-
tation by up to 36 per year.
CONCLUSION
The rapidly growing burden of ESRD, in terms of hu-
man suffering and financial costs, is a major public health
problem that will stretch the health care systems of all
countries. It is critical that we continue to find more and
more cost-effective ways to provide renal replacement
therapy for ESRD patients. However, the real, long-term
solution can only lie with the prevention of ESRD. In this
regard, more data on the efficacy and cost-effectiveness
of various approaches to prevent ESRD are urgently
needed.
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